Scholarlink

Lung diseases are among the leading causes of death worldwide. Still, noncommunicable pulmonary diseases, such as chronic obstructive pulmonary disease (COPD), and interstitial lung disease (ILD), are lacking curative pharmacotherapies. Either degradation or excessive production of altered pulmonary extracellular matrix (ECM) is a common key feature of those devastating diseases, respectively. Recapitulating those pathological changes in miniaturized cell culture models is key for phenotypic drug discovery approaches targeting the ECM for novel pharmacotherapies in pulmonary disease. We describe here a phenotypic immunofluorescence-based high-content/high-throughput assay in 384-well plate format to measure ECM deposition activity by primary human lung fibroblasts (phLFs) in a pulmonary fibrosis disease context.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Phenotypic Drug Screening for Novel Antifibrotic Therapeutics in Lung Health

  • 实验方案

  • 发表日期：

    2026年

查看全文
  • Xin Wei,
  • Arun Kumar Verma,
  • Kevin Merchant,
  • Diana Porras-Gonzalez,
  • Joshua Jäger,
  • Melanie Wögrath,
  • Lin Shen,
  • Ali Önder Yildirim,
  • Michael Gerckens,
  • Gerald Burgstaller

摘要

Lung diseases are among the leading causes of death worldwide. Still, noncommunicable pulmonary diseases, such as chronic obstructive pulmonary disease (COPD), and interstitial lung disease (ILD), are lacking curative pharmacotherapies. Either degradation or excessive production of altered pulmonary extracellular matrix (ECM) is a common key feature of those devastating diseases, respectively. Recapitulating those pathological changes in miniaturized cell culture models is key for phenotypic drug discovery approaches targeting the ECM for novel pharmacotherapies in pulmonary disease. We describe here a phenotypic immunofluorescence-based high-content/high-throughput assay in 384-well plate format to measure ECM deposition activity by primary human lung fibroblasts (phLFs) in a pulmonary fibrosis disease context.